Advertisement

Pruritus pp 363-377 | Cite as

Antihistamines

  • Caroline Gaudy-MarquesteEmail author
Chapter

Abstract

Histamine, first characterized nearly a century ago, is a key mediator of numerous biologic reactions including “allergic” ones, some of which are involved in usual dermatosis pathophysiology. Four types of receptors (H1, H2, H3, and H4) are individualized to date. Most of the effects of Histamine in allergic disease are mediated by the H1 receptors. Beside it role in early allergic response to antigen, Histamine also stimulate cytokines production and expression of cell-adhesion molecules and class II antigens, thus contributing to the late allergic response. Antihistamines and especially H1 ones are widely used in dermatological practice mainly in front of itching dermatosis. H1-antihistamines are an efficient treatment of urticaria where their efficacy is widely evidenced. Second generation molecules should be the first prescribed due to low side effects and best pharmacokinetic profile. All second generation molecules are equivalent in term of efficacy and most of them are free of sedative and cardiac side effects.

Keywords

Histamine Antihistamines Urticarial Itch Treatment Side effects Skin Atopic dermatitis Mastocyte Allergy 

References

  1. 1.
    Spitaler MM, Hammer A, Malli R, et al. Functional analysis of histamine receptor subtypes involved in endothelium-mediated relaxation of the human uterine artery. Clin Exp Pharmacol Physiol. 2002;29:711–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Sugimoto Y, Iba Y, Nakamura Y, et al. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy. 2004;34:456–9.PubMedCrossRefGoogle Scholar
  3. 3.
    McLeod RL, Mingo GG, Herczku C, et al. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol. 1999;13:391–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007;119:176–83.PubMedCrossRefGoogle Scholar
  5. 5.
    MacGlashan Jr D. Histamine: a mediator of inflammation. J Allergy Clin Immunol. 2003;112:S53–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489–98.PubMedCrossRefGoogle Scholar
  7. 7.
    Hill SJ, Ganellin CR, Timmerman H, et al. Classification of histamine receptors. Pharmacol Rev. 1997;49:253–78.PubMedGoogle Scholar
  8. 8.
    García-Cardeña G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392:821–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Bakker RA, Schoonus SB, Smit MJ, et al. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001;60:1133–42.PubMedGoogle Scholar
  10. 10.
    Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533(1–3):69–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Pincus SH, DiNapoli AM, Schooley WR. Superoxide production by eosinophils: activation by histamine. J Invest Dermatol. 1982;79:53–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol. 2001;166:4083–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Caron G, Delneste Y, Roelandts E, et al. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol. 2001;167:3682–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev. 1990;42:45–83.PubMedGoogle Scholar
  15. 15.
    Gantner F, Sakai K, Tusche MW, et al. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther. 2002;303:300–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Sirois J, Menard G, Moses AS, et al. Importance of histamine in the cytokine network in the lung through H2 and H3 receptors: stimulation of IL-10 production. J Immunol. 2000;164:2964–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Varty LM, Hey JA. Histamine H3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol. 2002;452:339–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Arrang JM. Le récepteur H3 de l’histamine: une cible pour de nouveaux médicaments. Ann Pharm Fr. 2003;61:173–84.PubMedGoogle Scholar
  19. 19.
    Schwartz JC, Morisset S, Rouleau A, et al. Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. J Neural Transm Suppl. 2003;64:1–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Nakamura T, Itadani H, Hidaka Y, et al. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun. 2000;279(2):615–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Cogé F, Guénin SP, Rique H, et al. Structure and expression of the human histamine H4-receptor gene. Biochem Biophys Res Commun. 2001;284:301–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Huang JF, Thurmond RL. The new biology of histamine receptors. Curr Allergy Asthma Rep. 2008;8(1):21–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Mirzahosseini A, Dalmadi B, Csutora P. Histamine receptor H4 regulates mast cell degranulation and IgE induced FcεRI upregulation in murine bone marrow-derived mast cells. Cell Immunol. 2013;283(1–2):38–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Cowden JM, Zhang M, Dunford PJ, et al. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol. 2010;130(4):1023–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Bakker RA, Wieland K, Timmerman H, et al. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol. 2000;387:R5–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Trzeciakowski J, Levi R. Antihistamines. In: Middleton Jr E, Reed CE, Ellis EF, editors. Allergy, principles and practice. 2nd ed. St Louis: Mosby; 1983. p. 575–92.Google Scholar
  27. 27.
    Passalacqua G, Canonica GW. Structure and classification of H1-antihistamines and overview of their activities. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker; 2002. p. 65–100.Google Scholar
  28. 28.
    Chen C, Hanson E, Watson JW, et al. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31:312–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 1999;29:116–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Robbins DK, Horton MW, Swan SK, et al. Pharmacokinetics of fexofenadine in patients with varying degrees of renal impairment. Pharm Res. 1996;13:S431. Abstract.Google Scholar
  31. 31.
    Matzke GR, Yeh J, Awni WM, et al. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy. 1987;59:25–30.PubMedGoogle Scholar
  32. 32.
    Walsh GM. The anti-inflammatory effects of the second generation antihistamines. Dermatol Ther. 2000;13:349–60.CrossRefGoogle Scholar
  33. 33.
    Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergol J Int. 2014;23(3):87–95.CrossRefGoogle Scholar
  34. 34.
    Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;33:1305–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Schatz M. H1-antihistamines in pregnancy and lactation. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker; 2002. p. 421–36.Google Scholar
  36. 36.
    Kallen B. Effect of perinatal (prenatal?) loratadine exposure on male rat reproductive organ development. Reprod Toxicol. 2004;18:453.PubMedCrossRefGoogle Scholar
  37. 37.
    Welch MJ, Meltzer EO, Simons ER. H1-antihistamines and the central nervous system. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker; 2002. p. 337–88.Google Scholar
  38. 38.
    García-Gea C, Martínez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008;28(6):675–85.PubMedCrossRefGoogle Scholar
  39. 39.
    Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32:133–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Vuurman E, Theunissen E, van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol. 2007;22:289–97.PubMedCrossRefGoogle Scholar
  41. 41.
    Vuurman EF, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol. 2004;60:307–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92:297–303.CrossRefGoogle Scholar
  43. 43.
    Conen S, Theunissen EL, Van Oers AC, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol. 2011;25(11):1517–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Angello JT, Druce HM. Drug effects on driving performance. Ann Intern Med. 2000;132(5):354–63.Google Scholar
  45. 45.
    Simons FE, Fraser TG, Reggin JD, et al. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol. 1996;7:22–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy. 1993;71:121–6.PubMedGoogle Scholar
  47. 47.
    Stevenson J, Cornah D, Evrard P, et al. Long-term evaluation of the impact of the h1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr Res. 2002;52:251–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Simons FE, Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol. 2007;18(6):535–42. Epub 2007 Jun 11.PubMedCrossRefGoogle Scholar
  49. 49.
    Yap YG, Camm AJ. Potential cardiotoxicity of H1-antihistamines. In: Simons FER, editor. Histamine and H1-antihistamines in allergic disease. New York: Marcel Dekker; 2002. p. 389–420.Google Scholar
  50. 50.
    Graff C, Struijk JJ, Kanters JK, et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig. 2012;32(5):339–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelines. Br J Clin Pharmacol. 2010;69(4):401–10.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Lawrence CM, Byrne JP. Eczematous eruption from oral diphenhydramine. Contact Dermatitis. 1981;7:276–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Tella R, Gaig P, Bartra J, et al. Urticaria to cetirizine. J Investig Allergol Clin Immunol. 2002;12:136–7.PubMedGoogle Scholar
  54. 54.
    Assouere MN, Mazereeuw-Hautier J, Bonafe JL. Toxidermie à deux antihistaminiques ayant une parenté chimique: la cétirizine et l’hydroxyzine. Ann Dermatol Venereol. 2002;129:1295–8.PubMedGoogle Scholar
  55. 55.
    Dwyer CM, Dick D. Fixed drug eruption caused by diphenhydramine. J Am Acad Dermatol. 1993;29:496–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Pionetti CH, Kien MC, Alonso A. Fixed drug eruption due to loratadine. Allergol Immunopathol (Madr). 2003;31:291–3.CrossRefGoogle Scholar
  57. 57.
    Fidan V, Fidan T. Fixed drug eruption against rupatadine fumarate. J Craniofac Surg. 2011;22(5):1682–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Roman IJ, Kassem N, Gural RP, et al. Suppression of histamine-induced wheal response by loratadine (SCH 29851) over 28 days in man. Ann Allergy. 1986;57:253–6.PubMedGoogle Scholar
  59. 59.
    Snyman JR, Sommers DK, Gregorowski MD, et al. Effect of cetirizine, ketotifen and chlorpheniramine on the dynamics of the cutaneous hypersensitivity reaction: a comparative study. Eur J Clin Pharmacol. 1992;42:359–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther. 1987;42:265–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy. 1996;26:1092–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Denham KJ, Boutsiouki P, Clough GF, et al. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res. 2003;52:424–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88:190–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Pontasch MJ, White LJ, Bradford JC. Oral agents in the management of urticaria: patient perception of effectiveness and level of satisfaction with treatment. Ann Pharmacother. 1993;27:730–1.PubMedGoogle Scholar
  65. 65.
    Watson NT, Weiss EL, Harter PM. Famotidine in the treatment of acute urticaria. Clin Exp Dermatol. 2000;25:186–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Moscati RM, Moore GP. Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. Ann Emerg Med. 1990;19:12–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000;36:462–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung. 1992;42:119–1121.Google Scholar
  69. 69.
    Brostoff J, Fitzharris P, Dunmore C, et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy. 1996;51:320–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother. 1996;30:1075–9.PubMedGoogle Scholar
  71. 71.
    Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double blind comparative study with clemastine. Ann Allergy. 1989;62:322–5.PubMedGoogle Scholar
  72. 72.
    Kalis B. Double blind multicenter comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs. 1996;52:30634.CrossRefGoogle Scholar
  73. 73.
    Kulthanan K, Gritiyarangsan P, Sitakalin C, et al. Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. J Med Assoc Thai. 2001;84:153–9.PubMedGoogle Scholar
  74. 74.
    Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48:535–41.PubMedCrossRefGoogle Scholar
  75. 75.
    Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double blind, placebo controlled, parallel, multicenter study. Int J Dermatol. 2006;45:469–74.PubMedCrossRefGoogle Scholar
  76. 76.
    Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double blind, randomized, placebo controlled multicenter study. Allergy. 2007;62:539–46.PubMedCrossRefGoogle Scholar
  77. 77.
    Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–28.PubMedCrossRefGoogle Scholar
  78. 78.
    Sussman G, Jancelewicz Z. Controlled trial of H1 antagonists in the treatment of chronic idiopathic urticaria. Ann Allergy. 1991;67:433–9.PubMedGoogle Scholar
  79. 79.
    Guerra L, Vincenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J E Acad Dermatol Venereol. 1994;3:148–52.CrossRefGoogle Scholar
  80. 80.
    Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2004;15:55–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Potter PC, Kapp A, Maurer M, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64(4):596–604.PubMedCrossRefGoogle Scholar
  82. 82.
    Dakhale GN, Shinde AT, Mahatme MS, et al. Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial. Int J Dermatol. 2014;53(5):643–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Maiti R, Jaida J, Raghavendra BN, et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol. 2011;10(12):1444–50.PubMedGoogle Scholar
  84. 84.
    Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676–82.PubMedCrossRefGoogle Scholar
  85. 85.
    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.PubMedCrossRefGoogle Scholar
  86. 86.
    Kaplan A, Ledford D, Ashby M. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Maurer M, Rosén K, Hsieh HJ. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–35.PubMedCrossRefGoogle Scholar
  88. 88.
    Saini SS, Bindslev-Jensen C, Maurer M. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75.PubMedCrossRefGoogle Scholar
  89. 89.
    Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. 1995;95:685–93.PubMedCrossRefGoogle Scholar
  90. 90.
    Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol. 1987;117:81–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110(3):484–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34(9):1401–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619–25.PubMedCrossRefGoogle Scholar
  94. 94.
    Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol. 1993;129:580–3.PubMedCrossRefGoogle Scholar
  95. 95.
    Boyle J, Marks P, Gibson JR. Acrivastine versus terfenadine in the treatment of symptomatic dermographism- a double blind, placebo-controlled study. J Int Med Res. 1989;17:9B–13.PubMedGoogle Scholar
  96. 96.
    Matthews CN, Kirby JD, James J, et al. Dermographism: reduction in weal size by chlorpheniramine and hydroxyzine. Br J Dermatol. 1973;88:279–82.PubMedCrossRefGoogle Scholar
  97. 97.
    Breathnach SM, Allen R, Ward AM, et al. Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy. Clin Exp Dermatol. 1983;8:463–76.PubMedCrossRefGoogle Scholar
  98. 98.
    Kaur S, Greaves M, Eftekhari N. Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study. Br J Dermatol. 1981;104:185–90.PubMedCrossRefGoogle Scholar
  99. 99.
    Kontou-Fili K, Maniatakou G, Demaka P, et al. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings. J Am Acad Dermatol. 1991;24:1090–3.PubMedCrossRefGoogle Scholar
  100. 100.
    Monfrecola G, Masturzo E, Riccardo AM, et al. Cetirizine for solar urticaria in the visible spectrum. Dermatology. 2000;200:334–5.PubMedCrossRefGoogle Scholar
  101. 101.
    Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Medeiros Jr M. Aquagenic urticaria. J Investig Allergol Clin Immunol. 1996;6:63–4.PubMedGoogle Scholar
  103. 103.
    Kobza Black A, Aboobaker J, Gibson JR, et al. Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study. Acta Derm Venereol. 1988;68:541–4.PubMedGoogle Scholar
  104. 104.
    Magerl M, Schmolke J, Siebenhaar F, et al. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy. 2007;62:1465–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol. 2015;3.Google Scholar
  107. 107.
    Krause K, Spohr A, Zuberbier T, et al. Up-dosing with bilastine results in improved effectiveness in cold contacturticaria. Allergy. 2013;68(7):921–8.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Nettis E, Pannofino A, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol. 2003;112:212–3.PubMedCrossRefGoogle Scholar
  109. 109.
    Nettis E, Colanardi MC, Soccio AL, et al. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double blind, placebo-controlled study. Br J Dermatol. 2006;155:1279–82.PubMedCrossRefGoogle Scholar
  110. 110.
    Bonadonna P, Lombardi C, Senna G, et al. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol. 2003;49:714–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Duc J, Pecoud A. Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report. Ann Allergy. 1986;56:355–7.PubMedGoogle Scholar
  112. 112.
    Irwin RB, Lieberman P, Friedman MM, et al. Mediator release in local heat urticaria: protection with combined H1 and H2 antagonists. J Allergy Clin Immunol. 1985;76:35–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol. 2004;93:142–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Grob JJ, Stalder JF, Ortonne JP, et al. Etude multicentrique randomisée en double insu, contre placebo, comparant les effets d’un traitement quotidien par desloratadine 5 mg ou placebo pendant six semaines sur la qualité de vie d’adultes atteints d’urticaire chronique idiopathique. Rev Fr Allergol Immunol Clin. 2004;44:127.Google Scholar
  116. 116.
    Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43:24–30.PubMedCrossRefGoogle Scholar
  117. 117.
    Mullol L, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63:5–28.PubMedCrossRefGoogle Scholar
  118. 118.
    Grob JJ, Auquier P, Dreyfus I, et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009;64(4):605–12.PubMedCrossRefGoogle Scholar
  119. 119.
    Reitamo S, Ansel JC, Luger TA. Itch in atopic dermatitis. J Am Acad Dermatol. 2001;45:S55–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Baraf CS. Treatment of pruritus in allergic dermatoses: an evaluation of the relative efficacy of cyproheptadine and hydroxyzine. Curr Ther Res Clin Exp. 1976;19:32–8.PubMedGoogle Scholar
  121. 121.
    Klein GL, Galant SP. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. Ann Allergy. 1980;44:142–5.PubMedGoogle Scholar
  122. 122.
    Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993;70:127–33.PubMedGoogle Scholar
  123. 123.
    La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy. 1994;73:117–22.PubMedGoogle Scholar
  124. 124.
    Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14:17–21.PubMedGoogle Scholar
  125. 125.
    Kawakami T, Kaminishi K, Soma Y, et al. Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. J Dermatol Sci. 2006;43(2):127–34.PubMedCrossRefGoogle Scholar
  126. 126.
    Yamanaka K, Motomura E, Noro Y. Olopatadine, a non-sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis. Exp Dermatol. 2015;24(3):227–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002;13:278–86.PubMedCrossRefGoogle Scholar
  128. 128.
    Warner JO, ETAC Study Group, Early Treatment of the Atopic Child. A double-blind, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months treatment and 18 months post treatment follow-up. J Allergy Clin Immunol. 2001;108:929–37.PubMedCrossRefGoogle Scholar
  129. 129.
    Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol. 2003;148:1212–21.PubMedCrossRefGoogle Scholar
  130. 130.
    Guzik TJ, Adamek-Guzik T, Bzowska M, Miedzobrodzki J, Czerniawska-Mysik G, Pryjma J. Influence of treating atopic dermatitis with oral antihistamine and topical steroids on selected parameters of cell and humoral immunity. Folia Med Cracov. 2002;43:79–93.PubMedGoogle Scholar
  131. 131.
    Murata Y, Song M, Kikuchi H. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42(2):129–39.PubMedCrossRefGoogle Scholar
  132. 132.
    Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. J Allergy Clin Immunol. 1993;92:520–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Gasior-Chrzan B, Falk ES. Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists. Dermatology. 1992;184:149–52.PubMedCrossRefGoogle Scholar
  134. 134.
    Czarnetzki BM. A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa. Dermatologica. 1983;166:44–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Povoa P, Ducla-Soares J, Fernandes A, et al. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med. 1991;229:475–7.PubMedCrossRefGoogle Scholar
  136. 136.
    Siebenhaar F, Förtsch A, Krause K. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68(7):949–52.PubMedCrossRefGoogle Scholar
  137. 137.
    Karppinen A, Kautiainen H, Reunala T, Petman L, Reunala T, Brummer-Korvenkontio H. Loratadine in the treatment of mosquito-bite-sensitive children. Allergy. 2000;55:668–71.PubMedCrossRefGoogle Scholar
  138. 138.
    Karppinen A, Petman L, Jekunen A, et al. Treatment of mosquito bites with ebastine: a field trial. Acta Derm Venereol. 2000;80:114–6.PubMedGoogle Scholar
  139. 139.
    Reunala T, Lappalainen P, Brummer-Korvenkontio H, et al. Cutaneous reactivity to mosquito bites: effect of cetirizine and development of anti-mosquito antibodies. Clin Exp Allergy. 1991;21:617–22.PubMedCrossRefGoogle Scholar
  140. 140.
    Karppinen A, Kautiainen H, Petman L, et al. Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. Allergy. 2002;57:534–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Karppinen A, Brummer-Korvenkontio H, Petman L, et al. Levocetirizine for treatment of immediate and delayed mosquito bite reactions. Acta Derm Venereol. 2006;86(4):329–31.PubMedCrossRefGoogle Scholar
  142. 142.
    Karppinen A, Brummer-Korvenkontio H, Reunala T, et al. Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy. J Eur Acad Dermatol Venereol. 2012;26(7):919–22.PubMedCrossRefGoogle Scholar
  143. 143.
    Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil. 2001;22:263–8.PubMedCrossRefGoogle Scholar
  144. 144.
    Dupont C, de Maubeuge J, Kotlar W, et al. Oxatomide in the treatment of pruritus senilis. A double-blind placebo-controlled trial. Dermatologica. 1984;169:348–53.PubMedCrossRefGoogle Scholar
  145. 145.
    Origoni M, Ferrari D, Rossi M, et al. Topical oxatomide: an alternative approach for the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet. 1996;55:259–64.PubMedCrossRefGoogle Scholar
  146. 146.
    Origoni M, Garsia S, Sideri M, et al. Efficacy of topical oxatomide in women with pruritus vulvae. Drugs Exp Clin Res. 1990;16:591–6.PubMedGoogle Scholar
  147. 147.
    Englisch W, Bauer CP. Dimethindene maleate in the treatment of pruritus caused by varizella zoster virus infection in children. Arzneimittelforschung. 1997;47:1233–5.PubMedGoogle Scholar
  148. 148.
    Marquez D, Ramonda C, Lauxmann JE. Uremic pruritus in hemodialysis patients: treatment with desloratidine versusgabapentin. J Bras Nefrol. 2012;34(2):148–52.PubMedCrossRefGoogle Scholar
  149. 149.
    Schulz S, Metz M, Siepmann D, et al. Antipruritic efficacy of a high-dosage antihistamine therapy. 2009;60:564–68Google Scholar

Copyright information

© Springer-Verlag London 2016

Authors and Affiliations

  1. 1.Department of Dermatology and Skin CancerTimoneMarseilleFrance

Personalised recommendations